{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:38:07Z","timestamp":1769243887028,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12916-017-0826-4","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T17:44:45Z","timestamp":1488390285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["News from the melanoma sessions of the European Cancer Congress 2017"],"prefix":"10.1186","volume":"15","author":[{"given":"Piotr","family":"Rutkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"issue":"Suppl 1","key":"826_CR1","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/S0959-8049(17)30484-7","volume":"72","author":"P Autier","year":"2017","unstructured":"Autier P, Koechlin A, Boniol M. 1144 \u2013 Prediction of numbers of melanoma deaths by 2050. Eur J Cancer. 2017;72 Suppl 1:S123\u20134. doi: 10.1016\/S0959-8049(17)30484-7 .","journal-title":"Eur J Cancer"},{"issue":"3","key":"826_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ejso.2016.12.001","volume":"43","author":"P Rutkowski","year":"2016","unstructured":"Rutkowski P. Introduction to the special issue of European Journal of Surgical Oncology: New roads in melanoma management. Eur J Surg Oncol. 2016;43(3):513\u20136. doi: 10.1016\/j.ejso.2016.12.001 .","journal-title":"Eur J Surg Oncol"},{"key":"826_CR3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","volume":"63","author":"C Garbe","year":"2016","unstructured":"Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016;63:201\u201317.","journal-title":"Eur J Cancer"},{"key":"826_CR4","unstructured":"NCCN Guidelines. Melanoma. Version 2.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#melanoma . Accessed Feb 2017."},{"key":"826_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","volume":"53","author":"S Ugurel","year":"2016","unstructured":"Ugurel S, Roehmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patient s with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016;53:125\u201334.","journal-title":"Eur J Cancer"},{"issue":"19","key":"826_CR6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb\u00e9 C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"826_CR7","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/S0959-8049(17)30485-9","volume":"72","author":"J Haanen","year":"2017","unstructured":"Haanen J, Blank C, van Thienen H, Mallo H, Adriaansz S, ter Meulen S, Madu M, Pronk L, van der Hiel L, van de Wiel B, Peeper D, van Akkooi A. 1146 \u2013 Downsizing of locally advanced stage III (bulky) BRAF V600E\/K melanoma with combination targeted therapy to achieve R0 resection. Eur J Cancer. 2017;72 Suppl 1:S124. doi: 10.1016\/S0959-8049(17)30485-9 .","journal-title":"Eur J Cancer"},{"key":"826_CR8","unstructured":"Amaria R. Treatment with neoadjuvant and adjuvant BRAF and MEK inhibitors is associated with improved relapse-free survival over standard-of-care therapy in patients with high risk resectable BRAF-mutant melanoma. Presentation at ECCO 2017. http:\/\/www.eccocongress.org\/Scientific-Programme\/Searchable-Programme . Accessed Feb 2017."},{"key":"826_CR9","unstructured":"Long G. Neoadjuvant therapy in bulky stage III melanoma: Are we there yet? Presentation at ECCO. 2017. http:\/\/www.eccocongress.org\/Scientific-Programme\/Searchable-Programme . Accessed Feb 2017."},{"issue":"Suppl 1","key":"826_CR10","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S0959-8049(17)30482-3","volume":"72","author":"GV Long","year":"2017","unstructured":"Long GV, Blank C, Ribas A, Mortier L, Carlino MS, Lotem M, Lorigan P, Neyns B, Petrella TM, Puzanov I, Richtig E, O'Day SJ, Masucci G, Lebbe C, Steven N, Lutzky J, Hille D, Ebbinghaus S, Ibrahim N, McNeil C. 1141 \u2013 Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Eur J Cancer. 2017;72 Suppl 1:S122\u20133. doi: 10.1016\/S0959-8049(17)30482-3 .","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"826_CR11","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/S0959-8049(17)30483-5","volume":"72","author":"M Butler","year":"2017","unstructured":"Butler M, Hamid O, Ribas A, Hodi FS, Walpole E, Dauad A, Arance A, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Robert C. 1142 \u2013 Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies. Eur J Cancer. 2017;72 Suppl 1:S123. doi: 10.1016\/S0959-8049(17)30483-5 .","journal-title":"Eur J Cancer"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-017-0826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T11:41:04Z","timestamp":1498390864000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-017-0826-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1186\/s12916-017-0826-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]},"article-number":"57"}}